Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Glaucoma UK

Glaucoma UK
Web Address: Glaucoma UK

 

Glaucoma UK, formerly the IGA, is a membership charity and we are passionate about making sure that people living with glaucoma have a say in how and where their care and treatment is delivered. We provide a host of support services to help people at all stages of their glaucoma journey, but we’re also here for the professionals too – providing support and resources and helping them keep in touch with what matters most to people with glaucoma.

Glaucoma UK is governed by a Board of Trustees who oversee our strategy, activity and performance, our finances and our polices. We are also supported by a Clinical Advisory Panel of 22 ophthalmology and optometry specialists and people living with glaucoma.

Further Resources

Close Popup